NEWS
2018

Annual General Meeting to be held 21 June 2018

8 June 2018
The annual general meeting of IC Targets is to be held at Oslo Science Park on 21 June 2018. Links to Notice is found below.
Notice of AGM (Norwegian only)
download
Annual report 2017 (Norwegian only)
download

Partnership with be imaging GmbH
27 April 2018
IC Targets announces that it has signed an agreement with b.e. imaging for the development of a mangafodipir MRI contrast agent. For more information please read the enclosed press release.
2017

License agreement with GE HealthCare
22 August 2017
Proceeds from the private placement of shares completed in August 2017 provided IC Targets with funding for entering into an exclusive world wide license agreement with GE Healthcare (GEHC) for use of mangafodipir tridosium ("mangafodipir") in vivo imaging. This agreement with GEHC is a key element of the revised business plan of IC Targets. With the agreement, the company has obtained access to the original contrast agent for use in clinical studies and subsequently also for commercialization of the patented proprietary cardiovascular indication.

Magnetic resonance imaging (MRI) is the fastest growing imaging modality, with more than 35 million procedures being performed in 2015 using Contrast Agents (CAs). All marketed MRI CAs contain the rare earth metal gadolinium (Gd). In recent years, regulatory health authorities have raised concerns about the use of Gd-based CAs (GBCAs). Thus, access to mangafodipir also provides IC Targets with a short term business opportunity within the original indication liver and pancreas MRI. Presently, manufacturing and distribution agreements are being explored.


Private placement of shares completed

22 August 2017
IC Targets has completed a private placement of shares with pre-emptive rights for existing shareholders. The NOK 4.0 million share issue was guaranteed fully subscribed by the shareholders MP Pensjon AS, Investor Corporate AS, Willy Eidsaunet and Per Jynge.

Share capital post capital increase is NOK 8.716.881. The number of shares is 8.716.881 each with nominal value NOK 1,-.

New certificate of registration (Norwegian only)
download

Annual General Meeting held 30 May 2017

30 May 2017
The annual general meeting of IC Targets was held at Oslo Science Park on May 30th. Links to Annual report and AGM minutes are found below.

Annual report 2017 (Norwegian only)
download
AGM minutes download (Norwegian only)
download
2016

Esben A. Nilssen steps down as CEO
15 February 2016
Esben A. Nilssen has informed the Board of Directors that he will step down as CEO of IC Targets within February 2016 to pursue other opportunities. Nilssen has been at the helm of IC Targets since the merger between IC Contrast and Epitarget in 2015. Håkon Sæterøy, currently Board member and majority shareholder, will assume the position as interim CEO.
2017

License agreement with GE HealthCare
22 August 2017
Proceeds from the private placement of shares completed in August 2017 provided IC Targets with funding for entering into an exclusive world wide license agreement with GE Healthcare (GEHC) for use of mangafodipir tridosium ("mangafodipir") in vivo imaging. This agreement with GEHC is a key element of the revised business plan of IC Targets. With the agreement, the company has obtained access to the original contrast agent for use in clinical studies and subsequently also for commercialization of the patented proprietary cardiovascular indication.

Magnetic resonance imaging (MRI) is the fastest growing imaging modality, with more than 35 million procedures being performed in 2015 using Contrast Agents (CAs). All marketed MRI CAs contain the rare earth metal gadolinium (Gd). In recent years, regulatory health authorities have raised concerns about the use of Gd-based CAs (GBCAs). Thus, access to mangafodipir also provides IC Targets with a short term business opportunity within the original indication liver and pancreas MRI. Presently, manufacturing and distribution agreements are being explored.


Private placement of shares completed

22 August 2017
IC Targets has completed a private placement of shares with pre-emptive rights for existing shareholders. The NOK 4.0 million share issue was guaranteed fully subscribed by the shareholders MP Pensjon AS, Investor Corporate AS, Willy Eidsaunet and Per Jynge.

Share capital post capital increase is NOK 8.716.881. The number of shares is 8.716.881 each with nominal value NOK 1,-.

New certificate of registration (Norwegian only)
download

Annual General Meeting held 30 May 2017

30 May 2017
The annual general meeting of IC Targets was held at Oslo Science Park on May 30th. Links to Annual report and AGM minutes are found below.

Annual report 2017 (Norwegian only)
download
AGM minutes download (Norwegian only)
download
2015

Ludvik Sandnes and Jan Fikkan elected new members of the IC-T board
17 June 2015
Ludvik Sandnes and Jan Fikkan were elected new Chairman of the Board and board member, respectively, at the IC-T Annual General Meeting 16 June 2015. Ludvik has more than 40 years experience from international banking and corporate finance, while Jan recently has lead GE Healthcare’s 800 employee Norwegian organisation. Read more about our new board members here.

Annual General Meeting 16 June 2015 - Downloads
1 June 2015
The annual general meeting of ICTargets will be held at Oslo Science Park 16 June at 10 am.
Annual Report (only in Norwegian)
download.
AGM agenda
download.

IC Targets appoints Dr Sigrid L. Fossheim as Chief Operating Officer
17 April 2015
Sigrid brings along more than 15 years of cross-functional managerial experience spanning from innovative research, pharmaceutical drug development to due diligence and investments. She has had managerial positions in both multinational and start-up companies and was recently Head of Biotech Investments at the Norwegian Cancer Society. Sigrid has an Executive MBA from the Norwegian School of Economics (NHH), Bergen, an MSc Pharm and PhD degree, both from the University of Oslo. Learn more about the company’s new Chief Operating Officer here.

New Board Members
26 February 2015
Professor Peter Aspelin (Karolinska, Sweden) and Willy Eidsaunet (former CEO IC Contrast and Senior Vice President GE Healthcare) were elected new board members of IC Targets after the merger with IC Contrast. Learn more about our non-executive directors here.

New Web Page and E-mail Addresses
23 February 2015
The new IC Targets web page was published today. IC Contast and Epitarget pages will soon close down. All email addresses will be transferred to @ictargets.com per of today, however, old emails will be active throughout 1H2015.

Merger Completed
11 February 2015
The merger between Epitarget and IC Contrast completed today. In the next weeks shareholders of IC Contrast will be transferred to IC Targets. The merged company IC Contrasts AS will reposition the magnetic resonance imaging (MRI) contrast agent mangafodipir for heart viability imaging.

2014

General Meeting Approves Merger with IC Contrast AS
19 December 2014
The General Meeting of shareholders today approved the merger of Epitarget AS and IC Contrast AS. The merged company will be named IC Targets AS.

Notice of extraordinary general meeting
5 December 2014
Epitarget calls the General Meeting of shareholders 19 December 2014 to approve the merger plan for the formation of IC targets AS. IC targets is the merger of Epitarget AS and IC Contrast AS. The shareholders of IC Contrast recently voted in favor of the merger.